All Oncology News

The FDA has granted a priority review designation to a supplemental new drug application for olaparib (Lynparza) for the treatment of patients with metastatic castration-resistant prostate cancer who have deleterious or suspected deleterious or somatic homologous recombination repair gene mutations, and who have also progressed on prior therapy with a new hormonal agent.

Neil Dunavin, MD, MS, highlights criteria to consider when approaching treatment selection for patients with myelofibrosis and discussed next steps for the field.

Charalambos (Babis) Andreadis, MD, MSCE, discusses immunotherapeutic advances in MCL and DLBCL based on data from the 2019 ASH Annual Meeting.

Thomas G. Martin, MD, discusses the current treatment approaches in multiple myeloma, as well as the agents that are generating excitement in relapsed/refractory patient populations.

The National Institute for Health and Care Excellence does not recommend larotrectinib for the treatment of advanced NTRK fusion–positive solid tumors in adults and children without satisfactory treatment options.

Kathleen Madden, FNP, MSN, AOCNP, APHN, discusses optimal management of adverse events associated with various therapies for patients with melanoma.

Saad Z. Usmani, MD, FACP, discusses the results of the CANDOR trial and the impact of these data on clinical practice in multiple myeloma.

Anna C. Pavlick, DO, discusses key trials that have shed light on how to best treat patients with newly diagnosed, metastatic melanoma.

He James Zhu, MD, PhD, discusses the role of elective nodal irradiation in breast cancer and research efforts that may answer some remaining questions with this modality.

David Polsky, MD, PhD, discusses the development and clinical utility of biomarkers in melanoma.

Jeffrey S. Weber, MD, PhD, discusses the activity of targeted therapy in metastatic melanoma, its adoption into the adjuvant setting, and the optimal use of immunotherapy in the space.

Howard A. "Skip" Burris, III, MD, FACP, FASCO, discusses the progress that has been made in metastatic triple-negative breast cancer and the work being done to broaden the utility of novel approaches.

The United Kingdom’s National Institute for Health and Care Excellence has issued guidelines recommending against pembrolizumab for use in treatment-naïve patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma whose tumors express PD-L1 with a combined positive score of ≥1.

The FDA has granted a priority review designation to a supplemental new drug application for rucaparib for the treatment of adult patients with BRCA1/2-mutant recurrent, metastatic castration-resistant prostate cancer.

The National Institute for Health and Care Excellence has recommended the use of olaparib as a maintenance treatment in adults with relapsed, platinum-sensitive, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer.

The FDA has granted a priority review designation to a supplemental biologics license application for the combination of nivolumab and ipilimumab for the first-line treatment of patients with metastatic or recurrent non–small cell lung cancer that does not have EGFR or ALK genomic tumor aberrations.

Stephanie L. Graff, MD, discusses the importance of using genomic risk to tailor treatment to patients with early-stage hormone receptor-positive, HER2-negative disease, the benefit of extended endocrine therapy, and ongoing research with CDK4/6 inhibitors and immunotherapy.

Nancy U. Lin, MD, discusses research focusing on CNS penetration in HER2-positive metastatic breast cancer.

Treatment with luspatercept-aamt reduced the severity of anemia in patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts who require red blood cell transfusions.

Atif Hussein, MD, discusses how the treatment of patients with hepatocellular carcinoma and cholangiocarcinoma has evolved in recent years.

Erika P. Hamilton, MD, discusses research presented at the 2019 San Antonio Breast Cancer Symposium and how the data are impacting the treatment of patients with HER2-positive breast cancer.

Denise Yardley, MD, discusses the implications of CDK4/6 inhibitors in hormone receptor-positive/HER2-negative breast cancer. 

The first-line combination of sintilimab injection plus pemetrexed and platinum-based therapy showed a statistically significant improvement in progression-free survival compared with chemotherapy and placebo in patients with advanced or recurrent nonsquamous non–small cell lung cancer who did not harbor EGFR or ALK abnormalities, according to an interim analysis of the phase III ORIENT-11 trial.

Investigators at John Theurer Cancer Center at Hackensack University Medical Center in New Jersey are the first to report poor adherence to genomic profiling guidelines for four biomarkers of metastatic colorectal cancer used to predict response to therapy, choose the most effective treatment, and improve outcomes — showing that only 40% of patients had their tumors tested.

The FDA has granted a priority review designation to a supplemental new drug application for the combination of olaparib and bevacizumab for the maintenance treatment of patients with advanced ovarian cancer who are in complete or partial response to first-line platinum-based chemotherapy with bevacizumab.

The Association of Community Cancer Centers congratulates the entire oncology community on the achievement of the largest one-year drop in cancer mortality—the record decline in annual cancer deaths was measured from 2016 to 2017.

Experts from The Ohio State University Comprehensive Cancer Center–James highlighted exciting research being conducted at their institution.

Pablo Ferraro, MD, discusses some of the latest developments in pancreatic cancer treatment and the potential role of emerging modalities under exploration.

Faculty from a 2019 OncLive® State of the Science Summit™ on Gastrointestinal Malignancies highlight the exciting research being conducted at their respective institutions.

Investigators at John Theurer Cancer Center at Hackensack University Medical Center in New Jersey were part of the CANDOR global phase III clinical trial for patients with refractory multiple myeloma.